by Lucie AUBOURG Stephane Bancel, CEO and director of Moderna. Moderna CEO Stephane Bancel told AFP his company’s experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer. Globally there were an estimated 325,000 new melanoma...
Patricia McKnight December 16, 2022 A cancer vaccine based on the messenger RNA (mRNA) technology, provided alongside the checkpoint inhibitor pembrolizumab (Keytruda), has shown encouraging results in an open label phase 2b clinical trial. The trial found that the combination regimen reduced the risk of cancer recurrence or death among melanoma patients by 44% compared with pembrolizumab alone, according to the vaccine’s...
Delilah Alvarado Associate Editor The exterior of the Food And Drug Administration headquarters is seen on July 20, 2020, in White Oak, Maryland. Sarah Silbiger via Getty Images The Food and Drug Administration has authorized updated COVID-19 booster vaccines for emergency use, hoping the reformulated shots from partners Pfizer and BioNTech and Moderna can curb an...
by Lauran Neergaard Credit: Pixabay/CC0 Public Domain Moderna hopes to offer updated COVID-19 boosters in the fall that combine its original vaccine with protection against the omicron variant. On Tuesday, it reported a preliminary hint that such an approach might work. Today’s COVID-19 vaccines all are based on the original version of the coronavirus. But...
Credit: Pixabay/CC0 Public Domain Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company’s COVID-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would “allow for a fourth dose of our #COVID19 vaccine in adults 18 years of age...
by Kaiser Permanente Credit: Unsplash/CC0 Public Domain New Kaiser Permanente research published February 21, 2022 in Nature Medicine shows that while Moderna COVID-19 vaccine protection is strong against coronavirus infection by the Delta variant, it is not as strong against infection from the Omicron variant. Three doses of the Moderna COVID-19 vaccine were highly effective against hospitalization...
JANUARY 20, 2022 by Case Western Reserve University Credit: CC0 Public Domain A new study by researchers at the Case Western Reserve University School of Medicine finds those who received the Moderna COVID-19 mRNA vaccine are less likely to experience “breakthrough” COVID-19 cases, compared to recipients of the Pfizer-BioNTech mRNA vaccine. A vaccine breakthrough infection occurs...
Three US studies offer more evidence that third dose of COVID vaccine is highly effective against Omicron. A healthcare worker receives a Pfizer COVID-19 booster shot in the United States [File: Lynne Sladky/AP]Published On 22 Jan 202222 Jan 2022 Booster shots of the Pfizer-BioNTech and Moderna vaccines have proven highly effective at preventing Omicron-related hospitalisations, according to...
by Tamar Nordenberg, Veterans Affairs Research Communications Credit: Pixabay/CC0 Public Domain In the first head-to-head comparison of the effectiveness of the Pfizer-BioNTech and Moderna COVID-19 vaccines, researchers examined the electronic health records of veterans who had received each vaccine. Both vaccines were highly effective in preventing COVID-19 outcomes such as documented infection, hospitalization, and death....
by Frances D’emilio Moderna co-founder and chairman Noubar Afeyan listens to questions during an interview with the Associated Press, in Rome, Monday, Oct. 11, 2021. Credit: AP Photo/Andrew Medichini Moderna has no plans to share the recipe for its COVID-19 vaccine because executives have concluded that scaling up the company’s own production is the best...
